EVFM (Evofem Biosciences) Cyclically Adjusted FCF per Share: $-5,797.02 (As of Mar. 2026)


What is Evofem Biosciences Cyclically Adjusted FCF per Share?

Evofem Biosciences EVFM -1.06% Cyclically Adjusted FCF per Share is $-5,797.02 as of Mar. 2026. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Evofem Biosciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.017. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-5,797.02 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-09), Evofem Biosciences's current stock price is $0.00935. Evofem Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-5,797.02. Evofem Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Evofem Biosciences  (OTCPK:EVFM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Evofem Biosciences Cyclically Adjusted FCF per Share Related Terms


Evofem Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Cyclically Adjusted FCF per Share Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -12,268.57 -11,343.10 0.00

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -10,103.84 -8,531.89 0.00 -5,797.02

EVFM vs LYRA, CLSDQ, ATXI: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Evofem Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Evofem Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evofem Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.017/330.2130*330.2130
=0.017

Current CPI (Mar. 2026) = 330.2130.

Evofem Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2,637.000 241.018 -3,612.891
201609 -3,123.000 241.428 -4,271.481
201612 -2,889.000 241.432 -3,951.363
201703 -6,069.000 243.801 -8,220.076
201706 -3,473.000 244.955 -4,681.798
201709 -4,751.000 246.819 -6,356.245
201712 -4,949.000 246.524 -6,629.067
201803 -2,267.250 249.554 -3,000.054
201806 -1,744.273 251.989 -2,285.741
201809 -637.714 252.439 -834.187
201812 -731.929 251.233 -962.025
201903 -548.429 254.202 -712.419
201906 -977.400 256.143 -1,260.039
201909 -577.000 256.759 -742.069
201912 -498.000 256.974 -639.933
202003 -575.808 258.115 -736.646
202006 -499.774 257.797 -640.162
202009 -839.977 260.280 -1,065.665
202012 -941.860 260.474 -1,194.032
202103 -804.864 264.877 -1,003.396
202106 -819.552 271.696 -996.064
202109 -462.976 274.310 -557.328
202112 -247.884 278.802 -293.594
202203 -235.787 287.504 -270.813
202206 -123.641 296.311 -137.787
202209 -3.685 296.808 -4.100
202212 -6.666 296.797 -7.417
202303 -3.886 301.836 -4.251
202306 -0.949 305.109 -1.027
202309 -0.003 307.789 -0.003
202312 -0.008 306.746 -0.009
202403 0.003 312.332 0.003
202406 -0.001 314.175 -0.001
202409 -0.005 315.301 -0.005
202412 -0.021 315.605 -0.022
202503 0.000 319.799 0.000
202506 -0.025 322.561 -0.026
202509 0.003 324.800 0.003
202512 0.000 324.054 0.000
202603 0.017 330.213 0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-5,797.02 mean?
Evofem Biosciences (EVFM) has a Cyclically Adjusted FCF per Share of $-5,797.02 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Cyclically Adjusted FCF per Share too high?
Evofem Biosciences' current Cyclically Adjusted FCF per Share is $-5,797.02.
How does Evofem Biosciences' Cyclically Adjusted FCF per Share compare to LYRA and CLSDQ?
Evofem Biosciences' Cyclically Adjusted FCF per Share of $-5,797.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Cyclically Adjusted FCF per Share is $-5,797.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 6.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-5,797.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Cyclically Adjusted FCF per Share is $-5,797.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.